The FDA has approved an expanded label for Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, which ...

Librela (bedinvetmab injection) is a monthly injectable monoclonal antibody, for which real-world drug experience data has ...

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

ROCKVILLE, Md. - Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company specializing in CNS diseases with an impressive 89% gross profit margin, has announced the FDA approval of a ...

Regulators have approved the drug as a treatment for weight loss, Type 2 diabetes and lowering the risk of heart attacks and ...

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...

(RTTNews) - Supernus Pharmaceuticals, Inc. (SUPN), a biopharmaceutical company, announced on Monday that the U.S. Food and Drug Administration or FDA has approved an updated label for Qelbree or ...

and Novo Nordisk can now claim to have the first medication in this class approved for chronic kidney disease. The FDA has expanded the label of Ozempic, approving the Novo Nordisk product for ...

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...